NVAX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
68.3M
+20.5%
56.7M
-59.4%
139.5M
-5.2%
147.1M
+108.9%
70.4M
Cost of Revenue
23.5M
+64.9%
14.2M
-53.6%
30.7M
+38.9%
22.1M
+2.8%
21.5M
Gross Profit
44.8M
+5.6%
42.5M
-61.0%
108.8M
-13.0%
125.0M
+155.4%
48.9M
Operating Expenses
76.1M
-21.8%
97.4M
-21.6%
124.2M
+12.1%
110.8M
-51.2%
227.0M
R&D
52.4M
-25.8%
70.7M
-26.0%
95.5M
+25.8%
75.9M
-22.8%
98.3M
SG&A
23.6M
-11.3%
26.7M
-7.3%
28.8M
-15.7%
34.1M
+7.8%
31.7M
Operating Income
-31281000
+43.0%
-54906000
-255.8%
-15430000
-208.4%
14.2M
+108.0%
-178018000
EBITDA
-28234000
+45.5%
-51850000
-319.2%
-12368000
-161.3%
20.2M
+127.1%
-74395000
Net Income
-31376000
+41.2%
-53387000
-462.5%
-9491000
-154.2%
17.5M
+108.7%
-202379000
EPS (Basic)
$-0.19
+40.6%
$-0.32
-433.3%
$-0.06
-154.5%
$0.11
+108.8%
$-1.25
EPS (Diluted)
$-0.19
+40.6%
$-0.32
-433.3%
$-0.06
-160.0%
$0.10
+108.0%
$-1.25
Shares (Diluted)
164.9M
+0.2%
164.6M
+0.8%
163.3M
-6.8%
175.2M
+7.9%
162.4M
Novavax (NVAX) — Financials